Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 160

1.

Essential structure of orexin 1 receptor antagonist YNT-707, part III: Role of the 14-hydroxy and the 3-methoxy groups in antagonistic activity toward the orexin 1 receptor in YNT-707 derivatives lacking the 4,5-epoxy ring.

Yamamoto N, Ohrui S, Okada T, Saitoh T, Kutsumura N, Nagumo Y, Irukayama-Tomobe Y, Ogawa Y, Ishikawa Y, Watanabe Y, Hayakawa D, Gouda H, Yanagisawa M, Nagase H.

Bioorg Med Chem. 2019 Apr 15;27(8):1747-1758. doi: 10.1016/j.bmc.2019.03.010. Epub 2019 Mar 5.

PMID:
30871861
2.

Acute Bilateral Oculomotor Nerve Palsy in an Adult Patient with Neisseria meningitidis.

Senda J, Adachi T, Tago M, Mori M, Imai H, Ogawa Y, Kawaguchi K.

Intern Med. 2019 Jun 1;58(11):1639-1642. doi: 10.2169/internalmedicine.2098-18. Epub 2019 Feb 1.

3.

Results of a nationwide survey on Japanese clinical practice in breast-conserving radiotherapy for breast cancer.

Aibe N, Karasawa K, Aoki M, Akahane K, Ogawa Y, Ogo E, Kanamori S, Kawamori J, Saito AI, Shiraishi K, Sekine H, Tachiiri S, Yoshimura M, Yamauchi C.

J Radiat Res. 2019 Jan 1;60(1):142-149. doi: 10.1093/jrr/rry095.

4.

Pull-down maneuver of stent graft for abdominal aortic aneurysm with accessory renal arteries.

Kawaguchi K, Ogawa Y, Imai H, Hayashi M, Kano N, Murase Y.

Cardiovasc Interv Ther. 2019 Jul;34(3):295-296. doi: 10.1007/s12928-018-0551-8. Epub 2018 Oct 3. No abstract available.

PMID:
30284184
5.

Inhibition of astrocytic adenosine receptor A2A attenuates microglial activation in a mouse model of Sandhoff disease.

Ogawa Y, Furusawa E, Saitoh T, Sugimoto H, Omori T, Shimizu S, Kondo H, Yamazaki M, Sakuraba H, Oishi K.

Neurobiol Dis. 2018 Oct;118:142-154. doi: 10.1016/j.nbd.2018.07.014. Epub 2018 Jul 17.

PMID:
30026035
6.

Clinical Utility of the Cognitive Test for Severe Dementia: Factor Analysis, Minimal Detectable Change, and Longitudinal Changes.

Tanaka H, Nagata Y, Ishimaru D, Ogawa Y, Fukuhara K, Nishikawa T.

Dement Geriatr Cogn Dis Extra. 2018 Jun 7;8(2):214-225. doi: 10.1159/000488937. eCollection 2018 May-Aug.

7.

Improvement in dysmyelination by the inhibition of microglial activation in a mouse model of Sandhoff disease.

Ogawa Y, Irisa M, Sano T, Yanagi Y, Furusawa E, Saito T, Yamanaka S, Itoh K, Sakuraba H, Oishi K.

Neuroreport. 2018 Aug 1;29(11):962-967. doi: 10.1097/WNR.0000000000001060.

PMID:
29847465
8.

Effects of the delta opioid receptor agonist KNT-127 on electroencephalographic activity in mice.

Saitoh A, Tominaga H, Ogawa Y, Irukayama-Tomobe Y, Yamada M, Yanagisawa M, Nagase H.

Pharmacol Rep. 2018 Apr;70(2):350-354. doi: 10.1016/j.pharep.2017.08.018. Epub 2017 Oct 28.

PMID:
29477045
9.

The combination assessment of lipid pool and thrombus by optical coherence tomography can predict the filter no-reflow in primary PCI for ST elevated myocardial infarction.

Negishi Y, Ishii H, Suzuki S, Aoki T, Iwakawa N, Kojima H, Harada K, Hirayama K, Mitsuda T, Sumi T, Tanaka A, Ogawa Y, Kawaguchi K, Murohara T.

Medicine (Baltimore). 2017 Dec;96(50):e9297. doi: 10.1097/MD.0000000000009297.

10.

Essential structure of orexin 1 receptor antagonist YNT-707, Part II: Drastic effect of the 14-hydroxy group on the orexin 1 receptor antagonistic activity.

Ohrui S, Yamamoto N, Saitoh T, Kutsumura N, Nagumo Y, Irukayama-Tomobe Y, Ogawa Y, Ishikawa Y, Watanabe Y, Hayakawa D, Gouda H, Yanagisawa M, Nagase H.

Bioorg Med Chem Lett. 2018 Feb 15;28(4):774-777. doi: 10.1016/j.bmcl.2017.12.069. Epub 2017 Dec 30.

PMID:
29338909
11.

Essential structure of orexin 1 receptor antagonist YNT-707, Part I: Role of the 4,5-epoxy ring for binding with orexin 1 receptor.

Yamamoto N, Ohrui S, Okada T, Yata M, Saitoh T, Kutsumura N, Nagumo Y, Irukayama-Tomobe Y, Ogawa Y, Ishikawa Y, Watanabe Y, Hayakawa D, Gouda H, Yanagisawa M, Nagase H.

Bioorg Med Chem Lett. 2017 Sep 1;27(17):4176-4179. doi: 10.1016/j.bmcl.2017.07.011. Epub 2017 Jul 4.

PMID:
28739044
12.

Therapeutic results of a novel enzyme-targeting radiosensitization treatment, Kochi oxydol-radiation therapy for unresectable carcinomas II, in patients with stage I primary breast cancer.

Aoyama N, Ogawa Y, Yasuoka M, Ohgi K, Iwasa H, Miyatake K, Yoshimatsu R, Yamanishi T, Hamada N, Tamura T, Kobayashi K, Murata Y, Miyamura M, Yamagami T.

Oncol Lett. 2017 Jun;13(6):4741-4747. doi: 10.3892/ol.2017.6074. Epub 2017 Apr 21.

13.

Abnormal differentiation of Sandhoff disease model mouse-derived multipotent stem cells toward a neural lineage.

Ogawa Y, Kaizu K, Yanagi Y, Takada S, Sakuraba H, Oishi K.

PLoS One. 2017 Jun 2;12(6):e0178978. doi: 10.1371/journal.pone.0178978. eCollection 2017.

14.

Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models.

Irukayama-Tomobe Y, Ogawa Y, Tominaga H, Ishikawa Y, Hosokawa N, Ambai S, Kawabe Y, Uchida S, Nakajima R, Saitoh T, Kanda T, Vogt K, Sakurai T, Nagase H, Yanagisawa M.

Proc Natl Acad Sci U S A. 2017 May 30;114(22):5731-5736. doi: 10.1073/pnas.1700499114. Epub 2017 May 15.

15.

Impaired Interpretation of Others' Behavior is Associated with Difficulties in Recognizing Pragmatic Language in Patients with Schizophrenia.

Fukuhara K, Ogawa Y, Tanaka H, Nagata Y, Nishida S, Haga D, Nishikawa T.

J Psycholinguist Res. 2017 Oct;46(5):1309-1318. doi: 10.1007/s10936-017-9497-8.

PMID:
28500472
16.

Therapeutic response to a novel enzyme-targeting radiosensitization treatment (KORTUC II) for residual lesions in patients with stage IV primary breast cancer, following induction chemotherapy with epirubicin and cyclophosphamide or taxane.

Aoyama N, Ogawa Y, Yasuoka M, Iwasa H, Miyatake K, Yoshimatsu R, Yamanishi T, Hamada N, Tamura T, Kobayashi K, Murata Y, Yamagami T, Miyamura M.

Oncol Lett. 2017 Jan;13(1):69-76. doi: 10.3892/ol.2016.5456. Epub 2016 Dec 1.

17.

FcRγ-dependent immune activation initiates astrogliosis during the asymptomatic phase of Sandhoff disease model mice.

Ogawa Y, Sano T, Irisa M, Kodama T, Saito T, Furusawa E, Kaizu K, Yanagi Y, Tsukimura T, Togawa T, Yamanaka S, Itoh K, Sakuraba H, Oishi K.

Sci Rep. 2017 Jan 13;7:40518. doi: 10.1038/srep40518.

18.

Design and Synthesis of Potent and Highly Selective Orexin 1 Receptor Antagonists with a Morphinan Skeleton and Their Pharmacologies.

Nagase H, Yamamoto N, Yata M, Ohrui S, Okada T, Saitoh T, Kutsumura N, Nagumo Y, Irukayama-Tomobe Y, Ishikawa Y, Ogawa Y, Hirayama S, Kuroda D, Watanabe Y, Gouda H, Yanagisawa M.

J Med Chem. 2017 Feb 9;60(3):1018-1040. doi: 10.1021/acs.jmedchem.6b01418. Epub 2017 Jan 18.

PMID:
28051300
19.

Peripherally administered orexin improves survival of mice with endotoxin shock.

Ogawa Y, Irukayama-Tomobe Y, Murakoshi N, Kiyama M, Ishikawa Y, Hosokawa N, Tominaga H, Uchida S, Kimura S, Kanuka M, Morita M, Hamada M, Takahashi S, Hayashi Y, Yanagisawa M.

Elife. 2016 Dec 30;5. pii: e21055. doi: 10.7554/eLife.21055.

20.

Bragg reflection band width and optical rotatory dispersion of cubic blue-phase liquid crystals.

Yoshida H, Anucha K, Ogawa Y, Kawata Y, Ozaki M, Fukuda JI, Kikuchi H.

Phys Rev E. 2016 Oct;94(4-1):042703. Epub 2016 Oct 21.

PMID:
27841625

Supplemental Content

Loading ...
Support Center